The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy and open-angle glaucoma.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...
Uniquity Bio Set to Start Phase 2 Clinical Trials in COPD & Asthma with Novel Anti-TSLP Monoclonal Antibody “Our investment in Uniquity Bio illustrates Blackstone Life Sciences’ commitment to finding, ...